Abstract:Background: The SARS-CoV-2 has been responsible for over 300,000 infections worldwide, however, epidemiological and clinical data of infected children are limited.Methods: We conducted a retrospective, multi-center study,and followed up with all children from the families with SARS-CoV-2 infected members in Zhejiang Province.We compared the epidemiological data between children and adults in the same families and analyzed the clinical characteristics andviral excretion time in pediatric cases.Findings: By February 29, 2020, 1298 cases from 883 families were confirmed with SARS-CoV-2 infection and 314 of which were children-families. Incidence of infection in children contacts was13·2% (43/325, 95%CI 9·5-16·9), which was lower than that in adult contacts (21·2%, 108/ 510, 95%CI 17·6-24·7). The mean age of 43 pediatric cases was 8·2 years and mean incubation period was 9·1 days. The peak of pediatric cases was two weeks later than that of adult cases. Forty (93·0%) were family clustering. Thirty-three children had COVID-19 (20 pneumonia) with mild symptoms and 10 were asymptomatic.The most common symptoms were fever (63·6%, 21/33) and cough (36·4%, 12/33). Four asymptomatic children had abnormal findings on chest CT. Fecal SARS-CoV-2 RNA detection was positive in 91·4% (32/35) cases and some children had viral excretion time over 60 days. Viral clearance time was not different among the groups treated with different antiviral regiments. No subsequent infection was observed in family contacts of fecal-viral-excreting children.Interpretation: Children have lower susceptibility of SARS-CoV-2 infection, milder clinical symptoms, longer incubation and fecal viral excretion time. Antiviral treatment did not improve the symptoms or shorten the time of viral excretion. Positive results of fecal SARS-CoV-2RNA detection were not used as indication for hospitalization or quarantine.Funding Statement: This work was supported by Zhejiang University Special Scientific Research fund for COVID-19 Prevention and Control, and funding from Ruian Science and Technology Bureau (MS2020023).Declaration of Interests: The authors have no conflicts of interest to declare.Ethics Approval Statement: The study was approved by both the institutional ethics board of Zhejiang Provincial CDC (T-043-R) and ethics commission of all designated hospitals for recruiting COVID-19 patients. Oral consents were obtained from the guardians of children.

Children's Vaccines Do Not Induce Cross Reactivity Against SARS-CoV

Differences In Clinical Features And Laboratory Results Between Adults And Children With Sars-Cov-2 Infection

Reflection on lower rates of COVID-19 in children: Does childhood immunizations offer unexpected protection?

What We Should Know about SARS-CoV-2 Infection in Children

Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

Characteristics of innate, humoral and cellular immunity in children with non-severe SARS-CoV-2 infection

Mild Cytokine Elevation, Moderate CD4+ T Cell Response and Abundant Antibody Production in Children with COVID-19

Lack of immune homology with vaccine preventable pathogens suggests childhood immunizations do not protect against SARS-CoV-2 through adaptive cross-immunity

Impact of cross-reactivity and herd immunity on SARS-CoV-2 pandemic severity

Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age

Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants in Children With Coronavirus Disease 2019, Multisystem Inflammatory Syndrome in Children, and After Two Doses of BNT162b2 Vaccination

Systems serology detects functionally distinct coronavirus antibody features in children and elderly

The Immunological Profile of SARS-CoV-2 Infection in Children Is Linked to Clinical Severity and Age

Efficacy of Inactivated SARS-CoV-2 Vaccination in Pediatric Hematology/oncology Patients: a Real-World Study

Reducedhumoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination

SARS-CoV2 coronavirus: so far polite with children. Debatable immunological and non-immunological evidence

SARS-CoV-2–specific mucosal immune response in vaccinated versus infected children

Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort

Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19

The Effect of Age and Comorbidities: Children vs. Adults in Their Response to SARS-CoV-2 Infection

Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children